다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기
Human gene therapy, v.33 no.17/18, 2022년, pp.879 - 888
Nathwani, Amit C. (Department of Haematology, UCL-Cancer Institute, London, United Kingdom) , McIntosh, Jenny (Department of Haematology, UCL-Cancer Institute, London, United Kingdom) , Sheridan, Rose (Freeline Therapeutics, Stevenage, United Kingdom.)
AI-Helper
Gene therapy is an exciting therapeutic concept that offers the promise of a cure for an array of inherited and acquired disorders. The liver has always been a key target for gene therapy as it controls essential biological processes including digestion, metabolism, detoxification, immunity, and blo...
Raper, Steven E, Chirmule, Narendra, Lee, Frank S, Wivel, Nelson A, Bagg, Adam, Gao, Guang-ping, Wilson, James M, Batshaw, Mark L. Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer. Molecular genetics and metabolism, vol.80, no.1, 148-158.
Hacein-Bey-Abina, Salima, Le Deist, Françoise, Carlier, Frédérique, Bouneaud, Cécile, Hue, Christophe, De Villartay, Jean-Pierre, Thrasher, Adrian J., Wulffraat, Nicolas, Sorensen, Ricardo, Dupuis-Girod, Sophie, Fischer, Alain, Davies, E. Graham, Kuis, Wietse, Leiva, Lilly, Cavazzana-Calvo, Marina. Sustained Correction of X-Linked Severe Combined Immunodeficiency by ex Vivo Gene Therapy. The New England journal of medicine, vol.346, no.16, 1185-1193.
Hacein-Bey-Abina, Salima, von Kalle, Christof, Schmidt, Manfred, Le Deist, Françoise, Wulffraat, Nicolas, McIntyre, Elisabeth, Radford, Isabelle, Villeval, Jean-Luc, Fraser, Christopher C., Cavazzana-Calvo, Marina, Fischer, Alain. A Serious Adverse Event after Successful Gene Therapy for X-Linked Severe Combined Immunodeficiency. The New England journal of medicine, vol.348, no.3, 255-256.
Hacein-Bey-Abina, S., Von Kalle, C., Schmidt, M., McCormack, M. P., Wulffraat, N., Leboulch, P., Lim, A., Osborne, C. S., Pawliuk, R., Morillon, E., Sorensen, R., Forster, A., Fraser, P., Cohen, J. I., de Saint Basile, G., Alexander, I., Wintergerst, U., Frebourg, T., Aurias, A., Stoppa-Lyonnet, D., Romana, S., Radford-Weiss, I., Gross, F., Valensi, F., Delabesse, E., Macintyre, E., Sigaux, F., Soulier, J., Leiva, L. E., Wissler, M., Prinz, C., Rabbitts, T. H., Le Deist, F., Fischer, A., Cavazzana-Calvo, M.. LMO2-Associated Clonal T Cell Proliferation in Two Patients after Gene Therapy for SCID-X1. Science, vol.302, no.5644, 415-419.
Balwani, Manisha, Sardh, Eliane, Ventura, Paolo, Peiró, Paula Aguilera, Rees, David C., Stölzel, Ulrich, Bissell, D. Montgomery, Bonkovsky, Herbert L., Windyga, Jerzy, Anderson, Karl E., Parker, Charles, Silver, Samuel M., Keel, Siobán B., Wang, Jiaan-Der, Stein, Penelope E., Harper, Pauline, Vassiliou, Daphne, Wang, Bruce, Phillips, John, Ivanova, Aneta, Langendonk, Janneke G., Kauppinen, Raili, Minder, Elisabeth, Horie, Yutaka, Penz, Craig, Chen, Jihong, Liu, Shangbin, Ko, John J., Sweetser, Marianne T., Garg, Pushkal, Vaishnaw, Akshay, Kim, Jae B., Simon, Amy R., Gouya, Laurent. Phase 3 Trial of RNAi Therapeutic Givosiran for Acute Intermittent Porphyria. The New England journal of medicine, vol.382, no.24, 2289-2301.
Adams, David, Gonzalez-Duarte, Alejandra, O’Riordan, William D., Yang, Chih-Chao, Ueda, Mitsuharu, Kristen, Arnt V., Tournev, Ivailo, Schmidt, Hartmut H., Coelho, Teresa, Berk, John L., Lin, Kon-Ping, Vita, Giuseppe, Attarian, Shahram, Planté-Bordeneuve, Violaine, Mezei, Michelle M., Campistol, Josep M., Buades, Juan, Brannagan III, Thomas H., Kim, Byoung J., Oh, Jeeyoung, Parman, Yesim, Sekijima, Yoshiki, Hawkins, Philip N., Solomon, Scott D., Polydefkis, Michael, Dyck, Peter J., Gandhi, Pritesh J., Goyal, Sunita, Chen, Jihong, Strahs, Andrew L., Nochur, Saraswathy V., Sweetser, Marianne T., Garg, Pushkal P., Vaishnaw, Akshay K., Gollob, Jared A., Suhr, Ole B.. Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis. The New England journal of medicine, vol.379, no.1, 11-21.
Mamcarz, Ewelina, Zhou, Sheng, Lockey, Timothy, Abdelsamed, Hossam, Cross, Shane J., Kang, Guolian, Ma, Zhijun, Condori, Jose, Dowdy, Jola, Triplett, Brandon, Li, Chen, Maron, Gabriela, Aldave Becerra, Juan C., Church, Joseph A., Dokmeci, Elif, Love, James T., da Matta Ain, Ana C., van der Watt, Hedi, Tang, Xing, Janssen, William, Ryu, Byoung Y., De Ravin, Suk See, Weiss, Mitchell J., Youngblood, Benjamin, Long-Boyle, Janel R., Gottschalk, Stephen, Meagher, Michael M., Malech, Harry L., Puck, Jennifer M., Cowan, Morton J., Sorrentino, Brian P.. Lentiviral Gene Therapy Combined with Low-Dose Busulfan in Infants with SCID-X1. The New England journal of medicine, vol.380, no.16, 1525-1534.
Boztug, Kaan, Schmidt, Manfred, Schwarzer, Adrian, Banerjee, Pinaki P., Díez, Inés Avedillo, Dewey, Ricardo A., Böhm, Marie, Nowrouzi, Ali, Ball, Claudia R., Glimm, Hanno, Naundorf, Sonja, Kühlcke, Klaus, Blasczyk, Rainer, Kondratenko, Irina, Maródi, László, Orange, Jordan S., von Kalle, Christof, Klein, Christoph. Stem-Cell Gene Therapy for the Wiskott-Aldrich Syndrome. The New England journal of medicine, vol.363, no.20, 1918-1927.
Magrin, Elisa, Semeraro, Michaela, Hebert, Nicolas, Joseph, Laure, Magnani, Alessandra, Chalumeau, Anne, Gabrion, Aurélie, Roudaut, Cécile, Marouene, Jouda, Lefrere, Francois, Diana, Jean-Sebastien, Denis, Adeline, Neven, Bénédicte, Funck-Brentano, Isabelle, Negre, Olivier, Renolleau, Sylvain, Brousse, Valentine, Kiger, Laurent, Touzot, Fabien, Poirot, Catherine, Bourget, Philippe, El Nemer, Wassim, Blanche, Stéphane, Tréluyer, Jean-Marc, Asmal, Mohammed, Walls, Courtney, Beuzard, Yves, Schmidt, Manfred, Hacein-Bey-Abina, Salima, Asnafi, Vahid, Guichard, Isabelle, Poirée, Maryline, Monpoux, Fabrice, Touraine, Philippe, Brouzes, Chantal, de Montalembert, Mariane, Payen, Emmanuel, Six, Emmanuelle, Ribeil, Jean-Antoine, Miccio, Annarita, Bartolucci, Pablo, Leboulch, Philippe, Cavazzana, Marina. Long-term outcomes of lentiviral gene therapy for the β-hemoglobinopathies: the HGB-205 trial. Nature medicine, vol.28, no.1, 81-88.
Maude, Shannon L., Laetsch, Theodore W., Buechner, Jochen, Rives, Susana, Boyer, Michael, Bittencourt, Henrique, Bader, Peter, Verneris, Michael R., Stefanski, Heather E., Myers, Gary D., Qayed, Muna, De Moerloose, Barbara, Hiramatsu, Hidefumi, Schlis, Krysta, Davis, Kara L., Martin, Paul L., Nemecek, Eneida R., Yanik, Gregory A., Peters, Christina, Baruchel, Andre, Boissel, Nicolas, Mechinaud, Francoise, Balduzzi, Adriana, Krueger, Joerg, June, Carl H., Levine, Bruce L., Wood, Patricia, Taran, Tetiana, Leung, Mimi, Mueller, Karen T., Zhang, Yiyun, Sen, Kapildeb, Lebwohl, David, Pulsipher, Michael A., Grupp, Stephan A.. Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia. The New England journal of medicine, vol.378, no.5, 439-448.
Cantore, Alessio, Naldini, Luigi. WFH State‐of‐the‐art paper 2020: In vivo lentiviral vector gene therapy for haemophilia. Haemophilia : the official journal of the World Federation of Hemophilia, vol.27, no.suppl, 122-125.
Nathwani, Amit C., Tuddenham, Edward G. D.. Haemophilia, the journey in search of a cure. 1960–2020. British journal of haematology, vol.191, no.4, 573-578.
McIntosh, Jenny, Lenting, Peter J., Rosales, Cecilia, Lee, Doyoung, Rabbanian, Samira, Raj, Deepak, Patel, Nishil, Tuddenham, Edward G. D., Christophe, Olivier D., McVey, John H., Waddington, Simon, Nienhuis, Arthur W., Gray, John T., Fagone, Paolo, Mingozzi, Federico, Zhou, Shang-Zhen, High, Katherine A., Cancio, Maria, Ng, Catherine Y. C., Zhou, Junfang, Morton, Christopher L., Davidoff, Andrew M., Nathwani, Amit C.. Therapeutic levels of FVIII following a single peripheral vein administration of rAAV vector encoding a novel human factor VIII variant. Blood, vol.121, no.17, 3335-3344.
Trapani, Ivana, Colella, Pasqualina, Sommella, Andrea, Iodice, Carolina, Cesi, Giulia, de Simone, Sonia, Marrocco, Elena, Rossi, Settimio, Giunti, Massimo, Palfi, Arpad, Farrar, Gwyneth J, Polishchuk, Roman, Auricchio, Alberto. Effective delivery of large genes to the retina by dual AAV vectors. EMBO molecular medicine, vol.6, no.2, 194-211.
Leborgne, Christian, Barbon, Elena, Alexander, Jeffrey M., Hanby, Hayley, Delignat, Sandrine, Cohen, Daniel M., Collaud, Fanny, Muraleetharan, Saghana, Lupo, Dan, Silverberg, Joseph, Huang, Karen, van Wittengerghe, Laetitia, Marolleau, Béatrice, Miranda, Adeline, Fabiano, Anna, Daventure, Victoria, Beck, Heena, Anguela, Xavier M., Ronzitti, Giuseppe, Armour, Sean M., Lacroix-Desmazes, Sebastien, Mingozzi, Federico. IgG-cleaving endopeptidase enables in vivo gene therapy in the presence of anti-AAV neutralizing antibodies. Nature medicine, vol.26, no.7, 1096-1101.
Nathwani, A.C., Tuddenham, E.G.D.. Epidemiology of coagulation disorders. Baillière's clinical haematology, vol.5, no.2, 383-439.
Manno, Catherine S, Arruda, Valder R, Pierce, Glenn F, Glader, Bertil, Ragni, Margaret, Rasko, John, Ozelo, Margareth C, Hoots, Keith, Blatt, Philip, Konkle, Barbara, Dake, Michael, Kaye, Robin, Razavi, Mahmood, Zajko, Albert, Zehnder, James, Nakai, Hiroyuki, Chew, Amy, Leonard, Debra, Wright, J Fraser, Lessard, Ruth R, Sommer, Jürg M, Tigges, Michael, Sabatino, Denise, Luk, Alvin, Jiang, Haiyan, Mingozzi, Federico, Couto, Linda, Ertl, Hildegund C, High, Katherine A, Kay, Mark A. Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nature medicine, vol.12, no.3, 342-347.
Nathwani, Amit C., Tuddenham, Edward G.D., Rangarajan, Savita, Rosales, Cecilia, McIntosh, Jenny, Linch, David C., Chowdary, Pratima, Riddell, Anne, Pie, Arnulfo Jaquilmac, Harrington, Chris, O'Beirne, James, Smith, Keith, Pasi, John, Glader, Bertil, Rustagi, Pradip, Ng, Catherine Y.C., Kay, Mark A., Zhou, Junfang, Spence, Yunyu, Morton, Christopher L., Allay, James, Coleman, John, Sleep, Susan, Cunningham, John M., Srivastava, Deokumar, Basner-Tschakarjan, Etiena, Mingozzi, Federico, High, Katherine A., Gray, John T., Reiss, Ulrike M., Nienhuis, Arthur W., Davidoff, Andrew M.. Adenovirus-Associated Virus Vector-Mediated Gene Transfer in Hemophilia B. The New England journal of medicine, vol.365, no.25, 2357-2365.
Nathwani, Amit C., Reiss, Ulreke M., Tuddenham, Edward G.D., Rosales, Cecilia, Chowdary, Pratima, McIntosh, Jenny, Della Peruta, Marco, Lheriteau, Elsa, Patel, Nishal, Raj, Deepak, Riddell, Anne, Pie, Jun, Rangarajan, Savita, Bevan, David, Recht, Michael, Shen, Yu-Min, Halka, Kathleen G., Basner-Tschakarjan, Etiena, Mingozzi, Federico, High, Katherine A., Allay, James, Kay, Mark A., Ng, Catherine Y.C., Zhou, Junfang, Cancio, Maria, Morton, Christopher L., Gray, John T., Srivastava, Deokumar, Nienhuis, Arthur W., Davidoff, Andrew M.. Long-Term Safety and Efficacy of Factor IX Gene Therapy in Hemophilia B. The New England journal of medicine, vol.371, no.21, 1994-2004.
Nathwani, Amit C., Gray, John T., McIntosh, Jenny, Ng, Catherine Y. C., Zhou, Junfang, Spence, Yunyu, Cochrane, Melanie, Gray, Elaine, Tuddenham, Edward G. D., Davidoff, Andrew M.. Safe and efficient transduction of the liver after peripheral vein infusion of self-complementary AAV vector results in stable therapeutic expression of human FIX in nonhuman primates. Blood, vol.109, no.4, 1414-1421.
Thomas, Clare E., Storm, Theresa A., Huang, Zan, Kay, Mark A.. Rapid Uncoating of Vector Genomes Is the Key toEfficient Liver Transduction with Pseudotyped Adeno-Associated VirusVectors. Journal of virology, vol.78, no.6, 3110-3122.
Gao, Guang-Ping, Alvira, Mauricio R., Wang, Lili, Calcedo, Roberto, Johnston, Julie, Wilson, James M.. Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy. Proceedings of the National Academy of Sciences of the United States of America, vol.99, no.18, 11854-11859.
Nathwani, Amit C, Reiss, Ulrike, Tuddenham, Edward, Chowdary, Pratima, McIntosh, Jenny, Riddell, Anne, Pie, Jun, Mahlangu, Johnny N, Recht, Michael, Shen, Yu-Min, Halka, Kathleen G., Meagher, Michael M, Nienhuis, Arthur W., Davidoff, Andrew M., Mangles, Sarah, Morton, Chris L, Junfang, Zhou, Radulescu, Vlad Calin. Adeno-Associated Mediated Gene Transfer for Hemophilia B:8 Year Follow up and Impact of Removing "Empty Viral Particles" on Safety and Efficacy of Gene Transfer. Blood, vol.132, no.suppl1, 491-491.
Miesbach, Wolfgang, Meijer, Karina, Coppens, Michiel, Kampmann, Peter, Klamroth, Robert, Schutgens, Roger, Tangelder, Marco, Castaman, Giancarlo, Schwable, Joachim, Bonig, Halvard, Seifried, Erhard, Cattaneo, Federica, Meyer, Christian, Leebeek, Frank W. G.. Gene therapy with adeno-associated virus vector 5–human factor IX in adults with hemophilia B. Blood, vol.131, no.9, 1022-1031.
Doshi, Bhavya S., Arruda, Valder R.. Gene therapy for hemophilia: what does the future hold?. Therapeutic advances in hematology, vol.9, no.9, 273-293.
Konkle, Barbara A., Walsh, Christopher E., Escobar, Miguel A., Josephson, Neil C., Young, Guy, von Drygalski, Annette, McPhee, Scott W. J., Samulski, R. Jude, Bilic, Ivan, de la Rosa, Maurus, Reipert, Birgit M., Rottensteiner, Hanspeter, Scheiflinger, Friedrich, Chapin, John C., Ewenstein, Bruce, Monahan, Paul E.. BAX 335 hemophilia B gene therapy clinical trial results: potential impact of CpG sequences on gene expression. Blood, vol.137, no.6, 763-774.
George, Lindsey A., Sullivan, Spencer K., Rasko, John E.J., Giermasz, Adam, Samelson-Jones, Benjamin J., Ducore, Jonathan M., Teitel, Jerome M., McGuinn, Catherine E., Runowski, Alexa R., Wright, Fraser, Anguela, Xavier M., High, Katherine A., Rybin, Denis, Murphy, John E., Rupon, Jeremy. Efficacy and Safety in 15 Hemophilia B Patients Treated with the AAV Gene Therapy Vector Fidanacogene Elaparvovec and Followed for at Least 1 Year. Blood, vol.134, no.1, 3347-3347.
George, Lindsey A., Sullivan, Spencer K., Giermasz, Adam, Rasko, John E.J., Samelson-Jones, Benjamin J., Ducore, Jonathan, Cuker, Adam, Sullivan, Lisa M., Majumdar, Suvankar, Teitel, Jerome, McGuinn, Catherine E., Ragni, Margaret V., Luk, Alvin Y., Hui, Daniel, Wright, J. Fraser, Chen, Yifeng, Liu, Yun, Wachtel, Katie, Winters, Angela, Tiefenbacher, Stefan, Arruda, Valder R., van der Loo, Johannes C.M., Zelenaia, Olga, Takefman, Daniel, Carr, Marcus E., Couto, Linda B., Anguela, Xavier M., High, Katherine A.. Hemophilia B Gene Therapy with a High-Specific-Activity Factor IX Variant. The New England journal of medicine, vol.377, no.23, 2215-2227.
Samelson-Jones, Ben J., Sullivan, Spencer K., Rasko, John E.J., Giermasz, Adam, George, Lindsey A., Ducore, Jonathan M., Teitel, Jerome M., McGuinn, Catherine E., O'Brien, Amanda, Winburn, Ian, Smith, Lynne M, Chhabra, Amit, Rupon, Jeremy. Follow-up of More Than 5 Years in a Cohort of Patients with Hemophilia B Treated with Fidanacogene Elaparvovec Adeno-Associated Virus Gene Therapy. Blood, vol.138, no.suppl1, 3975-3975.
Xue, Feng, Li, Huiyuan, Wu, Xia, Liu, Wei, Zhang, Feixu, Tang, Dingyue, Chen, Yunfei, Wang, Wentian, Chi, Ying, Zheng, Jing, Du, Zengmin, Jiang, Wei, Zhong, Chen, Wei, Jun, Zhu, Ping, Fu, Rongfeng, Liu, Xiaofan, Chen, Lingling, Pei, Xiaolei, Sun, Junjiang, Cheng, Tao, Yang, Renchi, Xiao, Zhang, Lei. Safety and activity of an engineered, liver-tropic adeno-associated virus vector expressing a hyperactive Padua factor IX administered with prophylactic glucocorticoids in patients with haemophilia B: a single-centre, single-arm, phase 1, pilot trial. The Lancet Haematology, vol.9, no.7, e504-e513.
Chowdary, Pratima, Shapiro, Susan, Makris, Mike, Evans, Gillian, Boyce, Sara, Talks, Kate, Dolan, Gerard, Reiss, Ulrike, Phillips, Mark, Riddell, Anne, Peralta, Maria R., Quaye, Michelle, Patch, David W., Tuddenham, Edward, Dane, Allison, Watissée, Marie, Long, Alison, Nathwani, Amit. Phase 1-2 Trial of AAVS3 Gene Therapy in Patients with Hemophilia B. The New England journal of medicine, vol.387, no.3, 237-247.
Rangarajan, Savita, Walsh, Liron, Lester, Will, Perry, David, Madan, Bella, Laffan, Michael, Yu, Hua, Vettermann, Christian, Pierce, Glenn F., Wong, Wing Y., Pasi, K. John. AAV5-Factor VIII Gene Transfer in Severe Hemophilia A. The New England journal of medicine, vol.377, no.26, 2519-2530.
Pasi, K. John, Rangarajan, Savita, Mitchell, Nina, Lester, Will, Symington, Emily, Madan, Bella, Laffan, Michael, Russell, Chris B., Li, Mingjin, Pierce, Glenn F., Wong, Wing Y.. Multiyear Follow-up of AAV5-hFVIII-SQ Gene Therapy for Hemophilia A. The New England journal of medicine, vol.382, no.1, 29-40.
Ozelo, Margareth C., Mahlangu, Johnny, Pasi, K. John, Giermasz, Adam, Leavitt, Andrew D., Laffan, Michael, Symington, Emily, Quon, Doris V., Wang, Jiaan-Der, Peerlinck, Kathelijne, Pipe, Steven W., Madan, Bella, Key, Nigel S., Pierce, Glenn F., O’Mahony, Brian, Kaczmarek, Radoslaw, Henshaw, Joshua, Lawal, Adebayo, Jayaram, Kala, Huang, Mei, Yang, Xinqun, Wong, Wing Y., Kim, Benjamin. Valoctocogene Roxaparvovec Gene Therapy for Hemophilia A. The New England journal of medicine, vol.386, no.11, 1013-1025.
Nathwani, Amit C, Tuddenham, Edward, Chowdary, Pratima, McIntosh, Jenny, Lee, Doyoung, Rosales, Cecilia, Phillips, Mark, Pie, Jun, Junfang, Zhou, Meagher, Michael M, Reiss, Ulrike, Davidoff, Andrew M., Morton, Chris L, Riddell, Anne. GO-8: Preliminary Results of a Phase I/II Dose Escalation Trial of Gene Therapy for Haemophilia a Using a Novel Human Factor VIII Variant. Blood, vol.132, no.suppl1, 489-489.
George, Lindsey A., Monahan, Paul E., Eyster, M. Elaine, Sullivan, Spencer K., Ragni, Margaret V., Croteau, Stacy E., Rasko, John E.J., Recht, Michael, Samelson-Jones, Benjamin J., MacDougall, Amy, Jaworski, Kristen, Noble, Robert, Curran, Marla, Kuranda, Klaudia, Mingozzi, Federico, Chang, Tiffany, Reape, Kathleen Z., Anguela, Xavier M., High, Katherine A.. Multiyear Factor VIII Expression after AAV Gene Transfer for Hemophilia A. The New England journal of medicine, vol.385, no.21, 1961-1973.
Visweshwar, Nathan, Harrington, Thomas J., Leavitt, Andrew D, Konkle, Barbara A., Giermasz, Adam, Stine, Kimo, Rupon, Jeremy, Di Russo, Gregory, Tseng, Li-Jung, de los Angeles Resa, Maria, Ganne, Florence, Agathon, Delphine, Plonski, Frank, Rouy, Didier, Cockroft, Bettina M., Fang, Annie, Arkin, Steven. Updated Results of the Alta Study, a Phase 1/2 Study of Giroctocogene Fitelparvovec (PF-07055480/SB-525) Gene Therapy in Adults with Severe Hemophilia a. Blood, vol.138, no.suppl1, 564-564.
Finn, Jonathan D., Nichols, Timothy C., Svoronos, Nikolaos, Merricks, Elizabeth P., Bellenger, Dwight A., Zhou, Shangshen, Simioni, Paolo, High, Katherine A., Arruda, Valder R.. The efficacy and the risk of immunogenicity of FIX Padua (R338L) in hemophilia B dogs treated by AAV muscle gene therapy. Blood, vol.120, no.23, 4521-4523.
10.1101/2022.07.19.22277425
D’Avola, Delia, López-Franco, Esperanza, Sangro, Bruno, Pañeda, Astrid, Grossios, Nadina, Gil-Farina, Irene, Benito, Alberto, Twisk, Jaap, Paz, María, Ruiz, Juan, Schmidt, Manfred, Petry, Harald, Harper, Pauline, de Salamanca, Rafael Enríquez, Fontanellas, Antonio, Prieto, Jesús, González-Aseguinolaza, Gloria. Phase I open label liver-directed gene therapy clinical trial for acute intermittent porphyria. Journal of hepatology : the journal of the European Association for the Study of the Liver, vol.65, no.4, 776-783.
Baruteau, Julien, Cunningham, Sharon C., Yilmaz, Berna Seker, Perocheau, Dany P., Eaglestone, Simon, Burke, Derek, Thrasher, Adrian J., Waddington, Simon N., Lisowski, Leszek, Alexander, Ian E., Gissen, Paul. Safety and efficacy of an engineered hepatotropic AAV gene therapy for ornithine transcarbamylase deficiency in cynomolgus monkeys. Molecular therapy. Methods & clinical development, vol.23, 135-146.
Simioni, Paolo, Tormene, Daniela, Tognin, Giulio, Gavasso, Sabrina, Bulato, Cristiana, Iacobelli, Nicholas P., Finn, Jonathan D., Spiezia, Luca, Radu, Claudia, Arruda, Valder R.. X-Linked Thrombophilia with a Mutant Factor IX (Factor IX Padua). The New England journal of medicine, vol.361, no.17, 1671-1675.
Nowrouzi, Ali, Penaud-Budloo, Magalie, Kaeppel, Christine, Appelt, Uwe, Le Guiner, Caroline, Moullier, Philippe, Kalle, Christof von, Snyder, Richard O, Schmidt, Manfred. Integration Frequency and Intermolecular Recombination of rAAV Vectors in Non-human Primate Skeletal Muscle and Liver. Molecular therapy : the journal of the American Society of Gene Therapy, vol.20, no.6, 1177-1186.
Li, Hojun, Malani, Nirav, Hamilton, Shari R., Schlachterman, Alexander, Bussadori, Giulio, Edmonson, Shyrie E., Shah, Rachel, Arruda, Valder R., Mingozzi, Federico, Fraser Wright, J., Bushman, Frederic D., High, Katherine A.. Assessing the potential for AAV vector genotoxicity in a murine model. Blood, vol.117, no.12, 3311-3319.
Nault, Jean-Charles, Datta, Shalini, Imbeaud, Sandrine, Franconi, Andrea, Mallet, Maxime, Couchy, Gabrielle, Letouzé, Eric, Pilati, Camilla, Verret, Benjamin, Blanc, Jean-Frédéric, Balabaud, Charles, Calderaro, Julien, Laurent, Alexis, Letexier, Mélanie, Bioulac-Sage, Paulette, Calvo, Fabien, Zucman-Rossi, Jessica. Recurrent AAV2-related insertional mutagenesis in human hepatocellular carcinomas. Nature genetics, vol.47, no.10, 1187-1193.
Donsante, Anthony, Miller, Daniel G., Li, Yi, Vogler, Carole, Brunt, Elizabeth M., Russell, David W., Sands, Mark S.. AAV Vector Integration Sites in Mouse Hepatocellular Carcinoma. Science, vol.317, no.5837, 477-477.
Kay, Mark A. AAV vectors and tumorigenicity. Nature biotechnology, vol.25, no.10, 1111-1113.
Mingozzi, Federico, Anguela, Xavier M., Pavani, Giulia, Chen, Yifeng, Davidson, Robert J., Hui, Daniel J., Yazicioglu, Mustafa, Elkouby, Liron, Hinderer, Christian J., Faella, Armida, Howard, Carolann, Tai, Alex, Podsakoff, Gregory M., Zhou, Shangzhen, Basner-Tschakarjan, Etiena, Wright, John Fraser, High, Katherine A.. Overcoming Preexisting Humoral Immunity to AAV Using Capsid Decoys. Science translational medicine, vol.5, no.194,
Grieger, Joshua C, Samulski, R Jude. Adeno-associated virus vectorology, manufacturing, and clinical applications.. Methods in enzymology, vol.507, 229-254.
Cecchini, S, Negrete, A, Kotin, R M. Toward exascale production of recombinant adeno-associated virus for gene transfer applications. Gene therapy, vol.15, no.11, 823-830.
Copyright KISTI. All Rights Reserved.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.